<b><i>Conclusions:</i></b> Our work identified Cpd.51 as a novel and safe Nrf2 activator and unveils a unique feedback mechanism involving Nrf2-DHRS3 interaction, providing a new therapeutic avenue for AIS. This evidence concerns the gene DHRS3 and androgen insensitivity syndrome.